Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Diseases
100%
Malignant Neoplasm
93%
Neoplasm
79%
Prostate Cancer
76%
Breast Cancer
73%
Radiation Therapy
72%
Overall Survival
63%
Chemotherapy
60%
Oncology
58%
Non Small Cell Lung Cancer
57%
Clear Cell Renal Cell Carcinoma
53%
Tumor
51%
Cancer
49%
Recurrent Disease
47%
Kidney Tumour
38%
Ovarian Cancer
32%
Lung Cancer
28%
Genetics
27%
Transitional Cell Carcinoma
27%
Biopsy Technique
24%
Colorectal Carcinoma
24%
Clinical Trial
23%
Metastatic Carcinoma
23%
BRCA1
22%
Chemoradiotherapy
22%
Partial Nephrectomy
22%
Systemic Therapy
21%
Hazard Ratio
21%
Progression Free Survival
21%
Cisplatin
21%
Immunotherapy
20%
Surgeon
20%
Gastrointestinal Stromal Tumor
20%
Adverse Event
18%
Melanoma
17%
Lymph Node
17%
Biological Marker
17%
Pancreas Cancer
17%
Bladder
16%
Lung
16%
External Beam Radiotherapy
16%
Prostate Specific Antigen
16%
Arm
16%
Nivolumab
15%
Intensity Modulated Radiation Therapy
15%
Cystectomy
15%
Kidney Cancer
15%
Krukenberg Tumor
15%
Health Care Cost
15%
Median Follow Up
15%
Odds Ratio
15%
Rectum Cancer
14%
Adenocarcinoma
14%
Adjuvant Therapy
14%
Quality of Life
14%
Neoadjuvant Chemotherapy
14%
Bladder Cancer
14%
Treatment Option
14%
Histology
13%
Prostatectomy
13%
BRCA2
13%
Pembrolizumab
13%
Head and Neck Cancer
13%
Oncologist
12%
Retroperitoneal Lymph Node Dissection
12%
Pelvis
12%
Immune Checkpoint Inhibitor
12%
Platinum
12%
Cancer Therapy
12%
Surgery
12%
Cytotechnology
11%
Colon Carcinoma
11%
Neoadjuvant Therapy
11%
Carcinoma
11%
Biochemical Recurrence
11%
Disease Free Survival
11%
Phase II Trials
11%
Penile prosthesis
11%
Brachytherapy
11%
Targeted Therapy
11%
Computer Assisted Tomography
11%
Stereotactic Body Radiation Therapy
10%
Pancreas Adenocarcinoma
10%
Systematic Review
10%
Morbidity
10%
Paclitaxel
10%
Meta-Analysis
10%
Kidney Metastasis
10%
Survival Rate
10%
Adjuvant Chemotherapy
10%
Muscle Invasive Bladder Cancer
10%
Distant Metastasis
9%
Pleura Mesothelioma
9%
Epidermal Growth Factor Receptor
9%
Radical Nephrectomy
9%
Clinician
9%
Primary Tumor
9%
Imatinib
9%
Ipilimumab
9%
Proportional Hazards Model
8%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
35%
Chemotherapy Regimen
31%
Prostate Cancer
30%
Malignant Neoplasm
30%
Diseases
27%
Neoplasm
24%
Overall Survival
21%
Cisplatin
15%
Nivolumab
14%
Renal Cell Carcinoma
14%
Progression Free Survival
14%
Adverse Event
13%
Clinical Trial
13%
Solid Malignant Neoplasm
12%
Paclitaxel
12%
Immunotherapy
12%
Carboplatin
11%
Ovary Cancer
11%
Biological Marker
11%
Breast Cancer
10%
Lung Cancer
10%
Platinum
10%
Gemcitabine
9%
Pembrolizumab
9%
Sunitinib
9%
Ipilimumab
8%
Gastrointestinal Stromal Tumor
8%
Phase II Trials
8%
Transitional Cell Carcinoma
8%
Androgen
8%
Prostate Specific Antigen
8%
Biochemical Recurrence
7%
Epidermal Growth Factor Receptor
7%
Docetaxel
7%
Recurrent Disease
6%
Protein Tyrosine Kinase Inhibitor
6%
Imatinib
6%
Bevacizumab
6%
Bladder Cancer
6%
Placebo
5%
Sodium Fluoride
5%
Immune Checkpoint Inhibitor
5%
Pharmacokinetics
5%
Monotherapy
5%
Pemetrexed
5%
Chemoradiation Therapy
5%
Colorectal Carcinoma
5%